Maria Antonia Vélez (@momavelez11) 's Twitter Profile
Maria Antonia Vélez

@momavelez11

Medical Oncologist @UCLA with a special interest in #lcsm and clinical research/trial design/disparities in access to trials. 🇨🇴 Tweets are my own.

ID: 1119774797729288194

calendar_today21-04-2019 01:28:10

1,1K Tweet

777 Followers

1,1K Following

Claire Zagorski, MSc, LP (@clairezagorski) 's Twitter Profile Photo

Utterly obsessed with this UCL researcher who won an Ig Nobel for showing that “Blue Zones” where people supposedly live well past 100 at unusual rates are actually just full of clerical errors and people committing pension fraud ucl.ac.uk/ioe/news/2024/…

Conquer Cancer, the ASCO Foundation (@conquercancerfd) 's Twitter Profile Photo

Celebrate the remarkable progress being made by Latina women in the field of cancer research and care with Gladys M. Rodriguez, MD, MS and Narjust Florez, MD, FASCO. Attend this free virtual event Oct. 2 and hear from the Women Who Conquer Cancer. Register today: brnw.ch/21wNbih

Celebrate the remarkable progress being made by Latina women in the field of cancer research and care with <a href="/GMRodriguez_MD/">Gladys M. Rodriguez, MD, MS</a> and <a href="/NarjustFlorezMD/">Narjust Florez, MD, FASCO</a>. 

Attend this free virtual event Oct. 2 and hear from the Women Who Conquer Cancer. Register today: brnw.ch/21wNbih
Yara Abdou (@yabdoumd) 's Twitter Profile Photo

The rise of industry-sponsored cancer clinical trial enrollment from 2008 to 2022, now surpassing NIH-sponsored trials, highlights a shift in oncology research priorities. This trend may limit opportunities for addressing broader, patient-centered questions that are not

The rise of industry-sponsored cancer clinical trial enrollment from 2008 to 2022, now surpassing NIH-sponsored trials, highlights a shift in oncology research priorities. This trend may limit opportunities for addressing broader, patient-centered questions that are not
Conquer Cancer, the ASCO Foundation (@conquercancerfd) 's Twitter Profile Photo

Celebrate the remarkable progress being made by Latina women in the field of cancer research and care with Gladys Rodriguez,MD, FASCO and Narjust Florez, MD, FASCO. Attend this free virtual event Oct. 2 and hear from the Women Who Conquer Cancer. Register today: brnw.ch/21wNmdo

Celebrate the remarkable progress being made by Latina women in the field of cancer research and care with <a href="/RodriguezGIMD/">Gladys Rodriguez,MD, FASCO</a> and <a href="/NarjustFlorezMD/">Narjust Florez, MD, FASCO</a>. 

Attend this free virtual event Oct. 2 and hear from the Women Who Conquer Cancer. Register today: brnw.ch/21wNmdo
Bishal Gyawali (@oncology_bg) 's Twitter Profile Photo

One thing I’ve learned over the years is that “You don’t have forever”. The currency you need to value the most is not money, but time.

Dimitrios Tsatiris MD (@drdimitrios) 's Twitter Profile Photo

Women in medicine: - Earn less. - Are less likely to be in leadership. - Have fewer research opportunities. - Spend 8.5 hours more per week on domestic responsibilities. Yet, they spend more time with patients and provide better care. The double standard needs to END.

Rafael_Narbona (@rafael_narbona) 's Twitter Profile Photo

7 DE OCTUBRE: UNA TRAGEDIA ANUNCIADA Según The New York Times, Israel conocía el ataque planificado por Hamás un año antes de que se produjera. Ha sido la excusa perfecta para cometer un genocidio en Gaza, impulsar la limpieza étnica en Cisjordania, invadir el Líbano y desafiar

7 DE OCTUBRE: UNA TRAGEDIA ANUNCIADA

Según The New York Times, Israel conocía el ataque planificado por Hamás un año antes de que se produjera. Ha sido la excusa perfecta para cometer un genocidio en Gaza, impulsar la limpieza étnica en Cisjordania, invadir el Líbano y desafiar
Vincent Rajkumar (@vincentrk) 's Twitter Profile Photo

I will continue to work with concerned colleagues to make leaders in medicine as well as professional organizations aware of the burdens of ABIM MOC and the need to approve alternative certifications like National Board of Physicians and Surgeons and not make all of us tied to one specific private organization

Anil Makam (@anilmakam) 's Twitter Profile Photo

this should've never been approved until clear safety profile established this is not definitive but adds fuel to the flames of the harm signal from trials fda failure